Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATP: Adjuvant Pyrotinib in Residual HER2+ Breast Cancer
NCT04254263Phase 3Recruiting
- Sponsor
- Renji Hospital
- Start
- Dec 2019
- Primary completion
- Aug 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of pyrotinib in breast cancer, sponsored by Renji Hospital. Started Dec 2019; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04254263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04254263.